Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of vehicle or drug treatment on gene expression in BxPC3 cell line

ABSTRACT: To investigate the effect of mutant p53 Y220C acetylation in gene expression, we treated BxPC3 (p53Y220C/-) cell lines with either DMSO, or PK9328 or MS172.

ORGANISM(S): Homo sapiens

PROVIDER: GSE277017 | GEO | 2024/09/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of vehicle or drug treatment on gene expression in p53-null and p53Y220C stable cell lines

Project description:To investigate the effect of mutant p53 Y220C acetylation in gene expression, we treated NCI-H1299 (WT) and (p53Y220C-stable) cell lines with either DMSO or MS78.

2024-09-11 | GSE229576 | GEO

Effect of vehicle or drug treatment on gene expression in BxPC3 cell line

Project description:Effect of vehicle or drug treatment on gene expression in BxPC3 cell line

| PRJNA1160227 | ENA

DDR1 knockdown in BXPC3 cell line

Project description:Examination of effect of stable DDR1 knockdown by shRNA on transcriptional profile in BXPC3 cell line to understand role of DDR1 in tumorigenesis. Transcriptional profiles of parental BXPC3 cell line was compared to BXPC3 cells stably transfected with non-target shRNA or DDR1 shRNA, N=3 for each condition.

2014-05-01 | E-GEOD-39207 | biostudies-arrayexpress

DDR1 knockdown in BXPC3 cell line

Project description:Examination of effect of stable DDR1 knockdown by shRNA on transcriptional profile in BXPC3 cell line to understand role of DDR1 in tumorigenesis.

2014-05-01 | GSE39207 | GEO

miRNA expression data from pancreatic ductal adenocarcinoma (PDAC) cell line BxPC3 and its cisplatin-resistant derivative BxPC3-R

Project description:Differential expression of miRNAs between parental and cisplatin-resistant PDAC cells was analyzed to elucidate the role of miRNAs in the acquired resistance of pancreatic cancer cells to cisplatin. Cisplatin-resistant BxPC3-R cells were developed from the parental BxPC3 cell line by culturing them in medium with step-wise increasing concentration of cisplatin.

2016-05-01 | GSE79506 | GEO

mRNA-seq of gemcitabine resistant pancreatic cancer cell line subclones derived from BxPC3

Project description:We generated gemcitabine resistant subclones from the human pancreatic cancer cell line BxPC3 using chronic low dose exposure to gemcitabine. Three gemcitabine resistant subclones (BxGR-80C, BxGR-120C and BxGR-360C) were sequenced in addition to BxPC3 cells.

2021-12-21 | E-MTAB-11186 | biostudies-arrayexpress

Chromatin occupancy assessment an AML cell line treated with vehicle control, BETi, MDM2i, or a drug combination (p53-bound profiles)

Project description:p53 chromatin occupancy changes in human OCI-AML3 cells treated with DMSO (vehicle control), the BET inhibitor CPI-203, the MDM2 inhibitor Nutlin-3a, or a combination of both drugs, were compared. Method: Genomic DNA from the OCI-AML3 cell line treated for 24 hrs with either DMSO, CPI-203, Nutlin-3a or a combination of both drugs was extracted, p53-bound chromatin was immunoprecipitated, then DNA was sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Bowtie2 and then analysed with MACS.

2020-11-04 | GSE132246 | GEO

Effect of ANO1 overexpression and/or oncogenic KRAS on gene expression of BxPC3 cells

Project description:RNA seq analysis was performed to assess the transcriptional profiles of BxPC3 cells with different status of ANO1 and KRAS.

2023-03-31 | GSE202825 | GEO

Deep sequencing of an AML cell line, with and without p53, treated with vehicle control, BETi, MDM2i, or a drug combination

Project description:Gene expression changes were compared in human OCI-AML3 cells, with or without p53 knock down, that were treated with DMSO (vehicle control), the BET inhibitor CPI-203, the MDM2 inhibitor Nutlin-3a, or a combination of both drugs. compared. Method: OCI-AML3 cells were transduced with either empty vector or vector expressing an shRA targeting p53. Cells were then treated for 24 hrs with either DMSO, CPI-203, Nutlin-3a or a combination of both drugs. PolyA mRNA was extracted, in triplicate, then sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Tophat2 and then analysed with Cufflinks. Keywords: Expression profiling by high throughput sequencing

2020-11-04 | GSE132245 | GEO

Amyloids induce glycocalyx mediated mechanotransduction

Project description:Pulldown PMEL NINTA; secretome BXPC3 DMSO vs BACE2 inhibitor (3I), insoluble fractione of secretome in IGR37; insoluble fractione of secretome in BXPC3

2024-01-09 | PXD041249 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data